ASEAN Point of Care Diagnostics Market by Product (Infectious Disease (TB, Hepatitis, STDs, HAIs), Glucose, Cardiometabolic, Pregnancy, Coagulation), Technology (Lateral Flow Assays, Biochemistry, MDx), End User (Home Care, Hospitals) - Forecast to 2030
The ASEAN point of care diagnostics market is expected to grow from USD 1.08 billion in 2025 to reach USD 1.36 billion in 2030, at a CAGR of 4.7% during the forecast period. Favorable government policies and funding investments drive the demand for Point of Care (POC) testing in the ASEAN region. Governments in these countries are increasingly supporting adopting such technologies to improve health access, reduce costs, and enhance patient outcomes. Through strategic partnerships, research initiatives, and nationwide screening campaigns, ASEAN governments promote using POC technologies to make healthcare accessible, lower costs, and improve patient outcomes. In several developing nations within the region, where health infrastructure is relatively underdeveloped, authorities encourage using POC devices to decentralize laboratory-based diagnostics and expand access to testing. These supportive initiatives are fostering the growth of POC diagnostics and creating new market opportunities for diagnostic firms in the ASEAN region.
“The infectious disease testing products segment is expected to register the highest growth rate in the ASEAN point of care diagnostics market, by product.”
Based on product, the ASEAN point of care diagnostics market is segmented into infectious disease testing products, glucose monitoring products, cardiometabolic testing products, coagulation monitoring products, pregnancy & fertility testing products, urinalysis testing products, cancer marker testing products, cholesterol testing products, hematology testing products, fecal occult testing products, drugs-of-abuse testing products, and other POC products. Among them, the infectious disease testing products segment is expected to grow at the highest CAGR, primarily driven by the region’s continuous efforts towards enhancing disease surveillance and outbreak control. Recurrent outbreaks of infectious diseases, in addition to the requirement for rapid diagnosis in both urban & rural healthcare facilities, are fueling the demand for effective POC solutions. Additionally, the rapid development of advanced molecular platforms and immunoassays will facilitate the effective and smooth identification of infectious diseases, further expanding adoption among ASEAN countries.
“By technology, the Biochemistry segment accounted for the largest market share in the ASEAN point of care diagnostics market in 2024.”
The ASEAN point of care diagnostics market is segmented by technology into lateral flow assays (immunoassays), rapid tests (molecular diagnostics), and biochemistry. In 2024, the Biochemistry segment accounted for the largest share of the market owing to its extensive usability in a variety of routine & essential diagnostic tests such as blood glucose checks, electrolyte analysis, liver function tests, and kidney function tests. The high prevalence of chronic & lifestyle-associated diseases like diabetes, cardiovascular disease, and kidney disorders in the ASEAN countries has also substantially necessitated the need for point-of-care testing solutions based on biochemistry. Moreover, the ease of operation, cost-effectiveness, and shorter turnaround time of biochemistry analyzers make them appropriate for decentralized healthcare environments such as community clinics, primary health centers, and emergency departments. The growing demand for early disease detection & diagnosis has further supported the implementation of biochemistry-based POC solutions in the ASEAN market.
“Vietnam is the fastest-growing market for point of care diagnostics in the ASEAN region”
The ASEAN market for point of care diagnostics is categorized into Vietnam, Laos, Cambodia, Malaysia, Myanmar, Philippines, Singapore, Thailand, Indonesia, and Brunei. Vietnam is expected to grow at the highest CAGR during the forecast period. Vietnam’s strong focus on strengthening its primary healthcare network and expanding nationwide screening programs—especially after the COVID-19 pandemic—has significantly increased the adoption of point-of-care diagnostic solutions in public and private healthcare facilities. Additionally, the country is committed to improving the early detection and management of infectious diseases, bolstered by its robust disease surveillance and monitoring systems, which will support long-term market growth. As reflected in its Joint External Evaluation and Global Health Security Index scores, Vietnam's impressive performance in global health security indicators highlights the healthcare system's growing capacity to implement point-of-care diagnostics in the coming years.
The break-up of the profile of primary participants in the ASEAN point of care diagnostics market:
Research Coverage:
This research report categorizes the ASEAN point of care diagnostics market by product (infectious disease testing products, glucose monitoring products, cardiometabolic testing products, coagulation monitoring products, pregnancy & fertility testing products, urinalysis testing products, cancer marker testing products, cholesterol testing products, hematology testing products, fecal occult testing products, drugs-of-abuse testing products, and other POC products), by technology [lateral flow assays (immunoassays), rapid tests (molecular diagnostics), and biochemistry], by end user (clinical laboratories, hospitals and critical care centers, outpatient settings and ambulatory care centers, home care settings, and other end users) and by country (Vietnam, Laos, Cambodia, Malaysia, Myanmar, Philippines, Singapore, Thailand, Indonesia, and Brunei). The report provides comprehensive information on the key factors influencing the growth of the ASEAN point-of-care diagnostics market, including drivers, restraints, opportunities, and challenges. It includes a detailed analysis of the major industry players, offering insights into their business overviews, solutions, key strategies, acquisitions, and agreements. Additionally, the report discusses new product and service launches and recent developments in the point-of-care diagnostics market. A competitive analysis of emerging startups within the ASEAN point-of-care diagnostics ecosystem is also included.
Reasons to buy this report:
The report will help market leaders and new entrants with information on the closest approximations of the revenue numbers for the ASEAN point of care diagnostics market and its subsegments. It will also help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following points:
“The infectious disease testing products segment is expected to register the highest growth rate in the ASEAN point of care diagnostics market, by product.”
Based on product, the ASEAN point of care diagnostics market is segmented into infectious disease testing products, glucose monitoring products, cardiometabolic testing products, coagulation monitoring products, pregnancy & fertility testing products, urinalysis testing products, cancer marker testing products, cholesterol testing products, hematology testing products, fecal occult testing products, drugs-of-abuse testing products, and other POC products. Among them, the infectious disease testing products segment is expected to grow at the highest CAGR, primarily driven by the region’s continuous efforts towards enhancing disease surveillance and outbreak control. Recurrent outbreaks of infectious diseases, in addition to the requirement for rapid diagnosis in both urban & rural healthcare facilities, are fueling the demand for effective POC solutions. Additionally, the rapid development of advanced molecular platforms and immunoassays will facilitate the effective and smooth identification of infectious diseases, further expanding adoption among ASEAN countries.
“By technology, the Biochemistry segment accounted for the largest market share in the ASEAN point of care diagnostics market in 2024.”
The ASEAN point of care diagnostics market is segmented by technology into lateral flow assays (immunoassays), rapid tests (molecular diagnostics), and biochemistry. In 2024, the Biochemistry segment accounted for the largest share of the market owing to its extensive usability in a variety of routine & essential diagnostic tests such as blood glucose checks, electrolyte analysis, liver function tests, and kidney function tests. The high prevalence of chronic & lifestyle-associated diseases like diabetes, cardiovascular disease, and kidney disorders in the ASEAN countries has also substantially necessitated the need for point-of-care testing solutions based on biochemistry. Moreover, the ease of operation, cost-effectiveness, and shorter turnaround time of biochemistry analyzers make them appropriate for decentralized healthcare environments such as community clinics, primary health centers, and emergency departments. The growing demand for early disease detection & diagnosis has further supported the implementation of biochemistry-based POC solutions in the ASEAN market.
“Vietnam is the fastest-growing market for point of care diagnostics in the ASEAN region”
The ASEAN market for point of care diagnostics is categorized into Vietnam, Laos, Cambodia, Malaysia, Myanmar, Philippines, Singapore, Thailand, Indonesia, and Brunei. Vietnam is expected to grow at the highest CAGR during the forecast period. Vietnam’s strong focus on strengthening its primary healthcare network and expanding nationwide screening programs—especially after the COVID-19 pandemic—has significantly increased the adoption of point-of-care diagnostic solutions in public and private healthcare facilities. Additionally, the country is committed to improving the early detection and management of infectious diseases, bolstered by its robust disease surveillance and monitoring systems, which will support long-term market growth. As reflected in its Joint External Evaluation and Global Health Security Index scores, Vietnam's impressive performance in global health security indicators highlights the healthcare system's growing capacity to implement point-of-care diagnostics in the coming years.
The break-up of the profile of primary participants in the ASEAN point of care diagnostics market:
- By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 – 30%
- By Designation: C-level - 27%, D-level - 18%, and Others - 55%
Research Coverage:
This research report categorizes the ASEAN point of care diagnostics market by product (infectious disease testing products, glucose monitoring products, cardiometabolic testing products, coagulation monitoring products, pregnancy & fertility testing products, urinalysis testing products, cancer marker testing products, cholesterol testing products, hematology testing products, fecal occult testing products, drugs-of-abuse testing products, and other POC products), by technology [lateral flow assays (immunoassays), rapid tests (molecular diagnostics), and biochemistry], by end user (clinical laboratories, hospitals and critical care centers, outpatient settings and ambulatory care centers, home care settings, and other end users) and by country (Vietnam, Laos, Cambodia, Malaysia, Myanmar, Philippines, Singapore, Thailand, Indonesia, and Brunei). The report provides comprehensive information on the key factors influencing the growth of the ASEAN point-of-care diagnostics market, including drivers, restraints, opportunities, and challenges. It includes a detailed analysis of the major industry players, offering insights into their business overviews, solutions, key strategies, acquisitions, and agreements. Additionally, the report discusses new product and service launches and recent developments in the point-of-care diagnostics market. A competitive analysis of emerging startups within the ASEAN point-of-care diagnostics ecosystem is also included.
Reasons to buy this report:
The report will help market leaders and new entrants with information on the closest approximations of the revenue numbers for the ASEAN point of care diagnostics market and its subsegments. It will also help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following points:
- Analysis of key drivers [Rising incidence of infectious diseases, increasing prevalence of chronic diseases, favorable government initiatives for POC testing, and the rising number of Public-Private Partnerships (PPPs)], opportunities (Gradual shift toward decentralized healthcare systems and availability of POC tests with multiplexing capabilities), restraints (Pricing pressure on manufacturers and stringent regulatory approval process for product commercialization), and challenges (Shortage of skilled healthcare providers and premium pricing of novel platforms) that influence the growth of the ASEAN point of care diagnostics market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the ASEAN point of care diagnostics market.
- Market Development: Comprehensive information about lucrative markets—the report analyses the ASEAN point of care diagnostics market across various countries.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the ASEAN point of care diagnostics market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Sysmex Corporation (Japan), and Danaher Corporation (US).
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 KEY STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key secondary sources
2.1.1.2 Key data from secondary sources
2.1.1.3 Key objectives
2.1.2 PRIMARY DATA
2.1.2.1 Key primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Company revenue estimation approach
2.2.1.2 Presentations of companies & primary interviews
2.2.1.3 Growth forecast
2.2.1.4 CAGR projections
2.2.2 TOP-DOWN APPROACH
2.3 DATA TRIANGULATION
2.4 MARKET SHARE ANALYSIS
2.5 RESEARCH ASSUMPTIONS
2.5.1 GROWTH RATE ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 ASEAN POINT OF CARE DIAGNOSTICS MARKET OVERVIEW
4.2 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2025 VS. 2030
4.3 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030
4.4 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030
4.5 ASEAN POINT OF CARE DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rising incidence of infectious diseases
5.2.1.2 Increasing prevalence of chronic diseases
5.2.1.3 Favorable government initiatives for POC testing
5.2.1.4 Rising number of public-private partnerships (PPPs)
5.2.2 RESTRAINTS
5.2.2.1 Pricing pressure on manufacturers
5.2.2.2 Stringent regulatory approval process for product commercialization
5.2.3 OPPORTUNITIES
5.2.3.1 Gradual shift toward decentralized healthcare systems
5.2.3.2 Availability of POC tests with multiplexing capabilities
5.2.4 CHALLENGES
5.2.4.1 Shortage of skilled healthcare providers
5.2.4.2 Premium pricing of novel platforms
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.4 PRICING ANALYSIS
5.4.1 INDICATIVE SELLING PRICE TREND OF POC TESTS, BY PRODUCT
5.4.2 INDICATIVE SELLING PRICE TREND OF GLUCOSE TEST STRIPS, BY KEY PLAYER
5.4.3 INDICATIVE SELLING PRICE TREND OF POC PREGNANCY TEST KITS,
BY COUNTRY
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 INVESTMENT & FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Lateral flow assays
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Molecular diagnostics
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 Biochemical technologies
5.10 PATENT ANALYSIS
5.11 TRADE ANALYSIS
5.11.1 IMPORT DATA FOR HS CODE 3822
5.11.2 EXPORT DATA FOR HS CODE 3822
5.12 KEY CONFERENCES & EVENTS, 2025–2026
5.13 REGULATORY ANALYSIS
5.13.1 REGULATORY LANDSCAPE
5.13.1.1 Vietnam
5.13.1.2 Laos
5.13.1.3 Cambodia
5.13.1.4 Malaysia
5.13.1.5 Myanmar
5.13.1.6 Philippines
5.13.1.7 Singapore
5.13.1.8 Thailand
5.13.1.9 Indonesia
5.13.1.10 Brunei
5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.14 PORTER’S FIVE FORCES ANALYSIS
5.14.1 THREAT OF NEW ENTRANTS
5.14.2 THREAT OF SUBSTITUTES
5.14.3 BARGAINING POWER OF BUYERS
5.14.4 BARGAINING POWER OF SUPPLIERS
5.14.5 INTENSITY OF COMPETITIVE RIVALRY
5.15 KEY STAKEHOLDERS & BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.15.2 KEY BUYING CRITERIA
5.16 IMPACT OF AI ON ASEAN POINT OF CARE DIAGNOSTICS MARKET
5.16.1 INTRODUCTION
5.16.2 MARKET POTENTIAL OF AI IN POC DIAGNOSTIC APPLICATIONS
5.16.3 AI USE CASES
5.16.4 KEY COMPANIES IMPLEMENTING AI
5.16.5 FUTURE OF AI IN ASEAN POINT OF CARE DIAGNOSTICS MARKET
6 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 GLUCOSE MONITORING PRODUCTS
6.2.1 GLUCOMETERS
6.2.1.1 Accurate monitoring of blood sugar levels to drive market
6.2.2 GLUCOSE TEST STRIPS
6.2.2.1 Increasing uptake of single-use products to fuel market
6.2.3 LANCETS
6.2.3.1 Increasing preference for home-based care to support market growth
6.3 INFECTIOUS DISEASE TESTING PRODUCTS
6.3.1 RESPIRATORY INFECTION TESTING PRODUCTS
6.3.1.1 TB testing products
6.3.1.1.1 High prevalence of tuberculosis cases to fuel market
6.3.1.2 Influenza testing products
6.3.1.2.1 Rising need for targeted treatment therapies to boost demand
6.3.1.3 Other respiratory infection testing products
6.3.2 MOSQUITO-BORNE DISEASE TESTING PRODUCTS
6.3.2.1 Rising incidence of malaria & dengue to boost demand
6.3.3 STD TESTING PRODUCTS
6.3.3.1 Need to reduce disease transmission rates to facilitate growth
6.3.4 HIV TESTING PRODUCTS
6.3.4.1 Growing awareness of HIV POC testing to boost demand
6.3.5 HAI TESTING PRODUCTS
6.3.5.1 Growing incidence of HAIs in healthcare settings to drive market
6.3.6 HEPATITIS TESTING PRODUCTS
6.3.6.1 Hepatitis B testing products
6.3.6.1.1 Increasing prevalence of liver infections to fuel market
6.3.6.2 Hepatitis C testing products
6.3.6.2.1 Rising need to combat hepatitis among high-risk subgroups to support market growth
6.3.7 OTHER INFECTIOUS DISEASE TESTING PRODUCTS
6.4 COVID-19 TESTING PRODUCTS
6.4.1 GRADUAL SHIFT TOWARDS SYNDROMIC TESTING TO SUPPORT MARKET GROWTH
6.5 CARDIOMETABOLIC TESTING PRODUCTS
6.5.1 CARDIAC MARKER TESTING PRODUCTS
6.5.1.1 Early detection of myocardial infarctions and acute coronary syndromes to fuel market
6.5.2 HBA1C TESTING PRODUCTS
6.5.2.1 Provision of long-term measurement in blood glucose control to boost demand
6.5.3 BLOOD GAS & ELECTROLYTE TESTING PRODUCTS
6.5.3.1 Monitoring of key parameters for pH and oxygen saturation to drive market
6.6 COAGULATION MONITORING PRODUCTS
6.6.1 HIGH INCIDENCE OF BLEEDING DISORDERS TO FUEL UPTAKE
6.7 PREGNANCY & FERTILITY TESTING PRODUCTS
6.7.1 GROWING AWARENESS OF SUSTAINABLE FAMILY PLANNING TO PROPEL MARKET
6.8 HEMATOLOGY TESTING PRODUCTS
6.8.1 RISING DEMAND FOR BLOOD TRANSFUSION PROCEDURES TO DRIVE MARKET
6.9 CANCER MARKER TESTING PRODUCTS
6.9.1 INCREASING PREFERENCE FOR PERSONALIZED ONCOLOGY THERAPEUTICS TO PROPEL MARKET
6.10 FECAL OCCULT TESTING PRODUCTS
6.10.1 FAVORABLE INITIATIVES FOR COLORECTAL CANCER SCREENING TO BOOST MARKET
6.11 CHOLESTEROL TESTING PRODUCTS
6.11.1 RISING OBESITY RATE CAUSED BY SEDENTARY LIFESTYLES TO DRIVE MARKET
6.12 URINALYSIS TESTING PRODUCTS
6.12.1 RISING PREVALENCE OF UTIS AND KIDNEY DISEASES TO DRIVE MARKET
6.13 DRUGS-OF-ABUSE TESTING PRODUCTS
6.13.1 HIGH CONSUMPTION OF ILLICIT DRUGS TO FUEL MARKET
6.14 OTHER POC PRODUCTS
7 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
7.2 BIOCHEMISTRY
7.2.1 PROVISION OF RAPID ONSITE RESULTS FOR CHRONIC CONDITIONS TO DRIVE MARKET
7.3 LATERAL FLOW ASSAYS (IMMUNOASSAYS)
7.3.1 INTEGRATION OF ELISA INTO DISPOSABLE TESTING STRIPS FOR COMPLEX LABORATORY ANALYSIS TO FUEL MARKET
7.4 RAPID TESTS (MOLECULAR DIAGNOSTICS)
7.4.1 ANALYSIS OF BIOLOGICAL MARKERS FOR RAPID DISEASE DETECTION TO PROPEL MARKET
8 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER
8.1 INTRODUCTION
8.2 HOME CARE SETTINGS
8.2.1 GROWING CONSUMER PREFERENCE FOR CONVENIENCE AND AFFORDABILITY TO PROPEL MARKET
8.3 CLINICAL LABORATORIES
8.3.1 MANAGEMENT OF HIGH PATIENT VOLUMES WITH AUTOMATED TESTING SOLUTIONS TO FUEL MARKET
8.4 HOSPITALS AND CRITICAL CARE CENTERS
8.4.1 RISING REQUIREMENT FOR RAPID POC TESTING IN EMERGENCY USE TO SUPPORT MARKET GROWTH
8.5 OUTPATIENT SETTINGS AND AMBULATORY CARE CENTERS
8.5.1 COST-EFFECTIVENESS OVER HOSPITALS TO BOOST MARKET GROWTH
8.6 OTHER END USERS
9 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY
9.1 INTRODUCTION
9.1.1 MACROECONOMIC OUTLOOK FOR ASEAN COUNTRIES
9.2 INDONESIA
9.2.1 RISING PUBLIC AWARENESS ABOUT PREVENTIVE HEALTHCARE TO DRIVE MARKET
9.2.2 MACROECONOMIC OUTLOOK FOR INDONESIA
9.3 THAILAND
9.3.1 EXPANDING GERIATRIC POPULATION AND SUBSEQUENT RISE IN CHRONIC DISEASES TO FUEL MARKET
9.3.2 MACROECONOMIC OUTLOOK FOR THAILAND
9.4 MALAYSIA
9.4.1 HIGH INCIDENCE OF DIABETES TO BOOST DEMAND
9.4.2 MACROECONOMIC OUTLOOK FOR MALAYSIA
9.5 PHILIPPINES
9.5.1 IMPROVED HEALTHCARE ACCESS AND INSURANCE COVERAGE TO FUEL ADOPTION
9.5.2 MACROECONOMIC OUTLOOK FOR PHILIPPINES
9.6 VIETNAM
9.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND FAVORABLE GOVERNMENT INITIATIVES TO PROPEL MARKET
9.6.2 MACROECONOMIC OUTLOOK FOR VIETNAM
9.7 SINGAPORE
9.7.1 INCREASING DEMAND FOR SPECIALIZED MEDICAL SERVICES TO BOOST MARKET
9.7.2 MACROECONOMIC OUTLOOK FOR SINGAPORE
9.8 MYANMAR
9.8.1 RISING NEED FOR AFFORDABLE DIAGNOSTIC SOLUTIONS TO DRIVE MARKET
9.8.2 MACROECONOMIC OUTLOOK FOR MYANMAR
9.9 CAMBODIA
9.9.1 RISING PREVALENCE OF NCDS TO SUPPORT MARKET GROWTH
9.9.2 MACROECONOMIC OUTLOOK FOR CAMBODIA
9.10 LAOS
9.10.1 NEED FOR DECENTRALIZED DIAGNOSTIC SOLUTIONS TO FUEL DEMAND
9.10.2 MACROECONOMIC OUTLOOK FOR LAOS
9.11 BRUNEI
9.11.1 GROWING NEED FOR COST-EFFECTIVE POC SOLUTIONS TO FUEL MARKET
9.11.2 MACROECONOMIC OUTLOOK FOR BRUNEI
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ASEAN POINT OF CARE DIAGNOSTICS MARKET
10.3 REVENUE ANALYSIS, 2022–2024
10.4 MARKET SHARE ANALYSIS, 2024
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
10.5.5 COMPANY FOOTPRINT, KEY PLAYERS, 2024
10.5.5.1 Company footprint
10.5.5.2 Country footprint
10.5.5.3 Product footprint
10.5.5.4 Technology footprint
10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
10.6.1 PROGRESSIVE COMPANIES
10.6.2 RESPONSIVE COMPANIES
10.6.3 DYNAMIC COMPANIES
10.6.4 STARTING BLOCKS
10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
10.6.5.1 Detailed list of key startups/SMEs
10.6.5.2 Competitive benchmarking of key startups/SMEs, by technology
10.6.5.3 Competitive benchmarking of key startups/SMEs, by country
10.7 COMPANY VALUATION & FINANCIAL METRICS
10.7.1 FINANCIAL METRICS
10.7.2 COMPANY VALUATION
10.8 BRAND/PRODUCT COMPARISON
10.9 COMPETITIVE SCENARIO
10.9.1 PRODUCT LAUNCHES & APPROVALS
10.9.2 DEALS
10.9.3 EXPANSIONS
11 COMPANY PROFILES
11.1 KEY PLAYERS
11.1.1 ABBOTT
11.1.1.1 Business overview
11.1.1.2 Products offered
11.1.1.3 Recent developments
11.1.1.3.1 Product approvals
11.1.1.3.2 Deals
11.1.1.4 MnM view
11.1.1.4.1 Key strengths
11.1.1.4.2 Strategic choices
11.1.1.4.3 Weaknesses & competitive threats
11.1.2 F. HOFFMANN-LA ROCHE LTD.
11.1.2.1 Business overview
11.1.2.2 Products offered
11.1.2.3 Recent developments
11.1.2.3.1 Product launches & approvals
11.1.2.3.2 Deals
11.1.2.4 MnM view
11.1.2.4.1 Key strengths
11.1.2.4.2 Strategic choices
11.1.2.4.3 Weaknesses & competitive threats
11.1.3 SIEMENS HEALTHINEERS AG
11.1.3.1 Business overview
11.1.3.2 Products offered
11.1.3.3 Recent developments
11.1.3.3.1 Product approvals
11.1.3.3.2 Deals
11.1.3.3.3 Expansions
11.1.3.4 MnM view
11.1.3.4.1 Key strengths
11.1.3.4.2 Strategic choices
11.1.3.4.3 Weaknesses & competitive threats
11.1.4 SYSMEX CORPORATION
11.1.4.1 Business overview
11.1.4.2 Products offered
11.1.4.3 Recent developments
11.1.4.3.1 Expansions
11.1.4.4 MnM view
11.1.4.4.1 Key strengths
11.1.4.4.2 Strategic choices
11.1.4.4.3 Weaknesses & competitive threats
11.1.5 DANAHER CORPORATION
11.1.5.1 Business overview
11.1.5.2 Products offered
11.1.5.3 MnM view
11.1.5.3.1 Key strengths
11.1.5.3.2 Strategic choices
11.1.5.3.3 Weaknesses and competitive threats
11.1.6 BD
11.1.6.1 Business overview
11.1.6.2 Products offered
11.1.6.3 Recent developments
11.1.6.3.1 Deals
11.1.6.3.2 Expansions
11.1.7 QUIDELORTHO CORPORATION
11.1.7.1 Business overview
11.1.7.2 Recent developments
11.1.7.2.1 Product approvals
11.1.7.2.2 Deals
11.1.7.2.3 Expansions
11.1.8 CARDINAL HEALTH
11.1.8.1 Business overview
11.1.8.2 Products offered
11.1.8.3 Recent developments
11.1.8.3.1 Deals
11.1.8.3.2 Expansions
11.1.9 BIOMЙRIEUX
11.1.9.1 Business overview
11.1.9.2 Products offered
11.1.9.3 Recent developments
11.1.9.3.1 Product approvals
11.1.9.3.2 Deals
11.1.10 EKF DIAGNOSTICS HOLDINGS PLC
11.1.10.1 Business overview
11.1.10.2 Products offered
11.1.10.3 Recent developments
11.1.10.3.1 Product launches
11.1.10.3.2 Deals
11.1.10.3.3 Expansions
11.1.11 THERMO FISHER SCIENTIFIC INC.
11.1.11.1 Business overview
11.1.11.2 Products offered
11.1.11.3 Recent developments
11.1.11.3.1 Product launches
11.1.11.3.2 Deals
11.1.12 ACCUBIOTECH, CO., LTD.
11.1.12.1 Business overview
11.1.12.2 Products offered
11.1.12.3 Recent developments
11.1.12.3.1 Product approvals
11.2 OTHER PLAYERS
11.2.1 BIOSYNEX SA
11.2.2 SD BIOSENSOR, INC.
11.2.3 SEKISUI DIAGNOSTICS
11.2.4 WERFEN
11.2.5 TRINITY BIOTECH
11.2.6 PTS DIAGNOSTICS
11.2.7 LIFESCAN IP HOLDINGS, LLC
11.2.8 CTK BIOTECH, INC.
11.2.9 WONDFO
11.2.10 ARKRAY, INC.
11.2.11 XIAMEN BOSON BIOTECH CO., LTD.
11.2.12 CREDO DIAGNOSTICS BIOMEDICAL PTE. LTD.
11.2.13 ANBIO BIOTECHNOLOGY INC.
11.2.14 SG DIAGNOSTICS
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 KEY STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key secondary sources
2.1.1.2 Key data from secondary sources
2.1.1.3 Key objectives
2.1.2 PRIMARY DATA
2.1.2.1 Key primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Company revenue estimation approach
2.2.1.2 Presentations of companies & primary interviews
2.2.1.3 Growth forecast
2.2.1.4 CAGR projections
2.2.2 TOP-DOWN APPROACH
2.3 DATA TRIANGULATION
2.4 MARKET SHARE ANALYSIS
2.5 RESEARCH ASSUMPTIONS
2.5.1 GROWTH RATE ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 ASEAN POINT OF CARE DIAGNOSTICS MARKET OVERVIEW
4.2 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2025 VS. 2030
4.3 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030
4.4 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030
4.5 ASEAN POINT OF CARE DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rising incidence of infectious diseases
5.2.1.2 Increasing prevalence of chronic diseases
5.2.1.3 Favorable government initiatives for POC testing
5.2.1.4 Rising number of public-private partnerships (PPPs)
5.2.2 RESTRAINTS
5.2.2.1 Pricing pressure on manufacturers
5.2.2.2 Stringent regulatory approval process for product commercialization
5.2.3 OPPORTUNITIES
5.2.3.1 Gradual shift toward decentralized healthcare systems
5.2.3.2 Availability of POC tests with multiplexing capabilities
5.2.4 CHALLENGES
5.2.4.1 Shortage of skilled healthcare providers
5.2.4.2 Premium pricing of novel platforms
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.4 PRICING ANALYSIS
5.4.1 INDICATIVE SELLING PRICE TREND OF POC TESTS, BY PRODUCT
5.4.2 INDICATIVE SELLING PRICE TREND OF GLUCOSE TEST STRIPS, BY KEY PLAYER
5.4.3 INDICATIVE SELLING PRICE TREND OF POC PREGNANCY TEST KITS,
BY COUNTRY
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 INVESTMENT & FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Lateral flow assays
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Molecular diagnostics
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 Biochemical technologies
5.10 PATENT ANALYSIS
5.11 TRADE ANALYSIS
5.11.1 IMPORT DATA FOR HS CODE 3822
5.11.2 EXPORT DATA FOR HS CODE 3822
5.12 KEY CONFERENCES & EVENTS, 2025–2026
5.13 REGULATORY ANALYSIS
5.13.1 REGULATORY LANDSCAPE
5.13.1.1 Vietnam
5.13.1.2 Laos
5.13.1.3 Cambodia
5.13.1.4 Malaysia
5.13.1.5 Myanmar
5.13.1.6 Philippines
5.13.1.7 Singapore
5.13.1.8 Thailand
5.13.1.9 Indonesia
5.13.1.10 Brunei
5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.14 PORTER’S FIVE FORCES ANALYSIS
5.14.1 THREAT OF NEW ENTRANTS
5.14.2 THREAT OF SUBSTITUTES
5.14.3 BARGAINING POWER OF BUYERS
5.14.4 BARGAINING POWER OF SUPPLIERS
5.14.5 INTENSITY OF COMPETITIVE RIVALRY
5.15 KEY STAKEHOLDERS & BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.15.2 KEY BUYING CRITERIA
5.16 IMPACT OF AI ON ASEAN POINT OF CARE DIAGNOSTICS MARKET
5.16.1 INTRODUCTION
5.16.2 MARKET POTENTIAL OF AI IN POC DIAGNOSTIC APPLICATIONS
5.16.3 AI USE CASES
5.16.4 KEY COMPANIES IMPLEMENTING AI
5.16.5 FUTURE OF AI IN ASEAN POINT OF CARE DIAGNOSTICS MARKET
6 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 GLUCOSE MONITORING PRODUCTS
6.2.1 GLUCOMETERS
6.2.1.1 Accurate monitoring of blood sugar levels to drive market
6.2.2 GLUCOSE TEST STRIPS
6.2.2.1 Increasing uptake of single-use products to fuel market
6.2.3 LANCETS
6.2.3.1 Increasing preference for home-based care to support market growth
6.3 INFECTIOUS DISEASE TESTING PRODUCTS
6.3.1 RESPIRATORY INFECTION TESTING PRODUCTS
6.3.1.1 TB testing products
6.3.1.1.1 High prevalence of tuberculosis cases to fuel market
6.3.1.2 Influenza testing products
6.3.1.2.1 Rising need for targeted treatment therapies to boost demand
6.3.1.3 Other respiratory infection testing products
6.3.2 MOSQUITO-BORNE DISEASE TESTING PRODUCTS
6.3.2.1 Rising incidence of malaria & dengue to boost demand
6.3.3 STD TESTING PRODUCTS
6.3.3.1 Need to reduce disease transmission rates to facilitate growth
6.3.4 HIV TESTING PRODUCTS
6.3.4.1 Growing awareness of HIV POC testing to boost demand
6.3.5 HAI TESTING PRODUCTS
6.3.5.1 Growing incidence of HAIs in healthcare settings to drive market
6.3.6 HEPATITIS TESTING PRODUCTS
6.3.6.1 Hepatitis B testing products
6.3.6.1.1 Increasing prevalence of liver infections to fuel market
6.3.6.2 Hepatitis C testing products
6.3.6.2.1 Rising need to combat hepatitis among high-risk subgroups to support market growth
6.3.7 OTHER INFECTIOUS DISEASE TESTING PRODUCTS
6.4 COVID-19 TESTING PRODUCTS
6.4.1 GRADUAL SHIFT TOWARDS SYNDROMIC TESTING TO SUPPORT MARKET GROWTH
6.5 CARDIOMETABOLIC TESTING PRODUCTS
6.5.1 CARDIAC MARKER TESTING PRODUCTS
6.5.1.1 Early detection of myocardial infarctions and acute coronary syndromes to fuel market
6.5.2 HBA1C TESTING PRODUCTS
6.5.2.1 Provision of long-term measurement in blood glucose control to boost demand
6.5.3 BLOOD GAS & ELECTROLYTE TESTING PRODUCTS
6.5.3.1 Monitoring of key parameters for pH and oxygen saturation to drive market
6.6 COAGULATION MONITORING PRODUCTS
6.6.1 HIGH INCIDENCE OF BLEEDING DISORDERS TO FUEL UPTAKE
6.7 PREGNANCY & FERTILITY TESTING PRODUCTS
6.7.1 GROWING AWARENESS OF SUSTAINABLE FAMILY PLANNING TO PROPEL MARKET
6.8 HEMATOLOGY TESTING PRODUCTS
6.8.1 RISING DEMAND FOR BLOOD TRANSFUSION PROCEDURES TO DRIVE MARKET
6.9 CANCER MARKER TESTING PRODUCTS
6.9.1 INCREASING PREFERENCE FOR PERSONALIZED ONCOLOGY THERAPEUTICS TO PROPEL MARKET
6.10 FECAL OCCULT TESTING PRODUCTS
6.10.1 FAVORABLE INITIATIVES FOR COLORECTAL CANCER SCREENING TO BOOST MARKET
6.11 CHOLESTEROL TESTING PRODUCTS
6.11.1 RISING OBESITY RATE CAUSED BY SEDENTARY LIFESTYLES TO DRIVE MARKET
6.12 URINALYSIS TESTING PRODUCTS
6.12.1 RISING PREVALENCE OF UTIS AND KIDNEY DISEASES TO DRIVE MARKET
6.13 DRUGS-OF-ABUSE TESTING PRODUCTS
6.13.1 HIGH CONSUMPTION OF ILLICIT DRUGS TO FUEL MARKET
6.14 OTHER POC PRODUCTS
7 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
7.2 BIOCHEMISTRY
7.2.1 PROVISION OF RAPID ONSITE RESULTS FOR CHRONIC CONDITIONS TO DRIVE MARKET
7.3 LATERAL FLOW ASSAYS (IMMUNOASSAYS)
7.3.1 INTEGRATION OF ELISA INTO DISPOSABLE TESTING STRIPS FOR COMPLEX LABORATORY ANALYSIS TO FUEL MARKET
7.4 RAPID TESTS (MOLECULAR DIAGNOSTICS)
7.4.1 ANALYSIS OF BIOLOGICAL MARKERS FOR RAPID DISEASE DETECTION TO PROPEL MARKET
8 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER
8.1 INTRODUCTION
8.2 HOME CARE SETTINGS
8.2.1 GROWING CONSUMER PREFERENCE FOR CONVENIENCE AND AFFORDABILITY TO PROPEL MARKET
8.3 CLINICAL LABORATORIES
8.3.1 MANAGEMENT OF HIGH PATIENT VOLUMES WITH AUTOMATED TESTING SOLUTIONS TO FUEL MARKET
8.4 HOSPITALS AND CRITICAL CARE CENTERS
8.4.1 RISING REQUIREMENT FOR RAPID POC TESTING IN EMERGENCY USE TO SUPPORT MARKET GROWTH
8.5 OUTPATIENT SETTINGS AND AMBULATORY CARE CENTERS
8.5.1 COST-EFFECTIVENESS OVER HOSPITALS TO BOOST MARKET GROWTH
8.6 OTHER END USERS
9 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY
9.1 INTRODUCTION
9.1.1 MACROECONOMIC OUTLOOK FOR ASEAN COUNTRIES
9.2 INDONESIA
9.2.1 RISING PUBLIC AWARENESS ABOUT PREVENTIVE HEALTHCARE TO DRIVE MARKET
9.2.2 MACROECONOMIC OUTLOOK FOR INDONESIA
9.3 THAILAND
9.3.1 EXPANDING GERIATRIC POPULATION AND SUBSEQUENT RISE IN CHRONIC DISEASES TO FUEL MARKET
9.3.2 MACROECONOMIC OUTLOOK FOR THAILAND
9.4 MALAYSIA
9.4.1 HIGH INCIDENCE OF DIABETES TO BOOST DEMAND
9.4.2 MACROECONOMIC OUTLOOK FOR MALAYSIA
9.5 PHILIPPINES
9.5.1 IMPROVED HEALTHCARE ACCESS AND INSURANCE COVERAGE TO FUEL ADOPTION
9.5.2 MACROECONOMIC OUTLOOK FOR PHILIPPINES
9.6 VIETNAM
9.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND FAVORABLE GOVERNMENT INITIATIVES TO PROPEL MARKET
9.6.2 MACROECONOMIC OUTLOOK FOR VIETNAM
9.7 SINGAPORE
9.7.1 INCREASING DEMAND FOR SPECIALIZED MEDICAL SERVICES TO BOOST MARKET
9.7.2 MACROECONOMIC OUTLOOK FOR SINGAPORE
9.8 MYANMAR
9.8.1 RISING NEED FOR AFFORDABLE DIAGNOSTIC SOLUTIONS TO DRIVE MARKET
9.8.2 MACROECONOMIC OUTLOOK FOR MYANMAR
9.9 CAMBODIA
9.9.1 RISING PREVALENCE OF NCDS TO SUPPORT MARKET GROWTH
9.9.2 MACROECONOMIC OUTLOOK FOR CAMBODIA
9.10 LAOS
9.10.1 NEED FOR DECENTRALIZED DIAGNOSTIC SOLUTIONS TO FUEL DEMAND
9.10.2 MACROECONOMIC OUTLOOK FOR LAOS
9.11 BRUNEI
9.11.1 GROWING NEED FOR COST-EFFECTIVE POC SOLUTIONS TO FUEL MARKET
9.11.2 MACROECONOMIC OUTLOOK FOR BRUNEI
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ASEAN POINT OF CARE DIAGNOSTICS MARKET
10.3 REVENUE ANALYSIS, 2022–2024
10.4 MARKET SHARE ANALYSIS, 2024
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
10.5.5 COMPANY FOOTPRINT, KEY PLAYERS, 2024
10.5.5.1 Company footprint
10.5.5.2 Country footprint
10.5.5.3 Product footprint
10.5.5.4 Technology footprint
10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
10.6.1 PROGRESSIVE COMPANIES
10.6.2 RESPONSIVE COMPANIES
10.6.3 DYNAMIC COMPANIES
10.6.4 STARTING BLOCKS
10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
10.6.5.1 Detailed list of key startups/SMEs
10.6.5.2 Competitive benchmarking of key startups/SMEs, by technology
10.6.5.3 Competitive benchmarking of key startups/SMEs, by country
10.7 COMPANY VALUATION & FINANCIAL METRICS
10.7.1 FINANCIAL METRICS
10.7.2 COMPANY VALUATION
10.8 BRAND/PRODUCT COMPARISON
10.9 COMPETITIVE SCENARIO
10.9.1 PRODUCT LAUNCHES & APPROVALS
10.9.2 DEALS
10.9.3 EXPANSIONS
11 COMPANY PROFILES
11.1 KEY PLAYERS
11.1.1 ABBOTT
11.1.1.1 Business overview
11.1.1.2 Products offered
11.1.1.3 Recent developments
11.1.1.3.1 Product approvals
11.1.1.3.2 Deals
11.1.1.4 MnM view
11.1.1.4.1 Key strengths
11.1.1.4.2 Strategic choices
11.1.1.4.3 Weaknesses & competitive threats
11.1.2 F. HOFFMANN-LA ROCHE LTD.
11.1.2.1 Business overview
11.1.2.2 Products offered
11.1.2.3 Recent developments
11.1.2.3.1 Product launches & approvals
11.1.2.3.2 Deals
11.1.2.4 MnM view
11.1.2.4.1 Key strengths
11.1.2.4.2 Strategic choices
11.1.2.4.3 Weaknesses & competitive threats
11.1.3 SIEMENS HEALTHINEERS AG
11.1.3.1 Business overview
11.1.3.2 Products offered
11.1.3.3 Recent developments
11.1.3.3.1 Product approvals
11.1.3.3.2 Deals
11.1.3.3.3 Expansions
11.1.3.4 MnM view
11.1.3.4.1 Key strengths
11.1.3.4.2 Strategic choices
11.1.3.4.3 Weaknesses & competitive threats
11.1.4 SYSMEX CORPORATION
11.1.4.1 Business overview
11.1.4.2 Products offered
11.1.4.3 Recent developments
11.1.4.3.1 Expansions
11.1.4.4 MnM view
11.1.4.4.1 Key strengths
11.1.4.4.2 Strategic choices
11.1.4.4.3 Weaknesses & competitive threats
11.1.5 DANAHER CORPORATION
11.1.5.1 Business overview
11.1.5.2 Products offered
11.1.5.3 MnM view
11.1.5.3.1 Key strengths
11.1.5.3.2 Strategic choices
11.1.5.3.3 Weaknesses and competitive threats
11.1.6 BD
11.1.6.1 Business overview
11.1.6.2 Products offered
11.1.6.3 Recent developments
11.1.6.3.1 Deals
11.1.6.3.2 Expansions
11.1.7 QUIDELORTHO CORPORATION
11.1.7.1 Business overview
11.1.7.2 Recent developments
11.1.7.2.1 Product approvals
11.1.7.2.2 Deals
11.1.7.2.3 Expansions
11.1.8 CARDINAL HEALTH
11.1.8.1 Business overview
11.1.8.2 Products offered
11.1.8.3 Recent developments
11.1.8.3.1 Deals
11.1.8.3.2 Expansions
11.1.9 BIOMЙRIEUX
11.1.9.1 Business overview
11.1.9.2 Products offered
11.1.9.3 Recent developments
11.1.9.3.1 Product approvals
11.1.9.3.2 Deals
11.1.10 EKF DIAGNOSTICS HOLDINGS PLC
11.1.10.1 Business overview
11.1.10.2 Products offered
11.1.10.3 Recent developments
11.1.10.3.1 Product launches
11.1.10.3.2 Deals
11.1.10.3.3 Expansions
11.1.11 THERMO FISHER SCIENTIFIC INC.
11.1.11.1 Business overview
11.1.11.2 Products offered
11.1.11.3 Recent developments
11.1.11.3.1 Product launches
11.1.11.3.2 Deals
11.1.12 ACCUBIOTECH, CO., LTD.
11.1.12.1 Business overview
11.1.12.2 Products offered
11.1.12.3 Recent developments
11.1.12.3.1 Product approvals
11.2 OTHER PLAYERS
11.2.1 BIOSYNEX SA
11.2.2 SD BIOSENSOR, INC.
11.2.3 SEKISUI DIAGNOSTICS
11.2.4 WERFEN
11.2.5 TRINITY BIOTECH
11.2.6 PTS DIAGNOSTICS
11.2.7 LIFESCAN IP HOLDINGS, LLC
11.2.8 CTK BIOTECH, INC.
11.2.9 WONDFO
11.2.10 ARKRAY, INC.
11.2.11 XIAMEN BOSON BIOTECH CO., LTD.
11.2.12 CREDO DIAGNOSTICS BIOMEDICAL PTE. LTD.
11.2.13 ANBIO BIOTECHNOLOGY INC.
11.2.14 SG DIAGNOSTICS
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
